Evidence map›Paper›PMID 42884560›Full record

ReviewNutrients2026

Probiotics in Celiac Disease: Current Evidence and Future Directions.

Christopher McLaughlin, Suneeta Krishnareddy

Abstract readReview
In one paragraph

Review in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Christopher McLaughlinDepartment of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA.ORCID 0000-0001-5319-2753
Suneeta KrishnareddyDepartment of Digestive and Liver Diseases, Columbia University Irving Medical Center, New York, NY 10032, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Celiac disease is often associated with gut microbiome alterations, which may play a role in autoimmunity to gluten peptides and upregulation of other autoinflammatory pathways. Probiotics of various formulations have been evaluated in attempts to normalize the gut microbiome and/or improve symptoms in Celiac disease, and even to potentially prevent Celiac disease in at-risk individuals. These studies have shown mixed results at best, and conclusions about the effectiveness of probiotics to these ends are limited by the variations across studies' probiotic formulation, dietary regimen, and clinical outcome markers. This leaves many encouraging future directions for further investigation into the potential beneficial role of probiotics on a pathophysiological and clinical level in Celiac disease.

Indexed as

Celiac DiseaseGastrointestinal MicrobiomeProbioticsDiet, Gluten-FreeGlutensHumansGlutensCeliac diseasegluten-free dietgut microbiomeprobiotics

Identifiers

PMID42884560
PMCPMC13666598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.